Oppenheimer maintains Legend Biotech at Perform, lowers price target to $25 from $40
Oppenheimer kept its 'Perform' rating on Legend Biotech but cut its price target to $25 from $40, a 37.5% reduction. This implies a 22.5% upside from the Nov 10 close of $20.41. Other recent analyst targets for the company range from $43 to $61.
How this was made

The 30-second read
Why it matters
The 37.5% target reduction reflects heightened risk perception, potentially triggering short‑term sell‑offs.
Market read
Target cut is the primary new information, offering a modest trading edge for short‑term positions.
What to watch
Upcoming clinical trial data or partnership announcements could offset the target reduction.
Background
Legend Biotech (LGND) is a Nasdaq‑listed biotech focused on oncology therapies. Analyst coverage is limited, making target changes a notable signal.
Market effects
May weigh on other small‑cap biotech stocks as analysts reassess sector risk.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Some investors may view the cut as an overreaction and see buying opportunity if pipeline progress remains unchanged.
Key entities
- AnalystOppenheimer
Equity research firm that issued the target cut.
- CompanyLegend Biotech
Biotech firm developing oncology treatments.


